Singapore markets closed

BioCryst Pharmaceuticals, Inc. (BCRX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
7.09+0.03 (+0.50%)
As of 02:32PM EDT. Market open.
Show:
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2023
31/12/2022
31/12/2021
31/12/2020
31/12/2019
Total revenue
355,395
331,412
270,827
157,170
17,812
-
Cost of revenue
5,115
4,661
6,594
7,264
1,676
-
Gross profit
350,280
326,751
264,233
149,906
16,136
-
Operating expenses
Research development
214,671
216,566
253,297
208,808
122,964
-
Selling general and administrative
225,391
213,894
159,371
118,818
67,929
-
Total operating expenses
440,062
430,460
412,668
327,626
190,893
-
Operating income or loss
-89,782
-103,709
-148,435
-177,720
-174,757
-
Interest expense
105,349
108,239
99,092
59,294
14,501
-
Total other income/expenses net
-29,880
-30,058
-1,983
55,143
-2,976
-
Income before tax
-208,581
-226,229
-244,383
-181,809
-182,814
-
Income tax expense
4
310
2,733
2,253
0
-
Income from continuing operations
-208,585
-226,539
-247,116
-184,062
-182,814
-
Net income
-208,585
-226,539
-247,116
-184,062
-182,814
-
Net income available to common shareholders
-208,585
-226,539
-247,116
-184,062
-182,814
-
Basic EPS
-1.25
-
-1.33
-1.03
-1.09
-0.94
Diluted EPS
-1.25
-
-1.33
-1.03
-1.09
-0.94
Basic average shares
188,555
-
185,908
179,117
167,267
115,600
Diluted average shares
188,555
-
185,908
179,117
167,267
115,600